Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Nederlands Tijdschrift Voor Geneeskunde
|
September 15, 2021
[The assessment of the price of a medicine: not only on the basis of the value for the patient]
Carla E M Hollak, Sibren van den Berg, Lonneke Timmers, et al.
Drug Discovery Today
|
July 11, 2024
Reliable business case for repurposing of existing medicines requires key changes in government policies
Samuel J de Visser, Sibren van den Berg, Arend Mosterd, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 28, 2025
Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products
Sibren van den Berg, Carolina E Hollak, Lonneke Timmers, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 15, 2022
Author Reply
Sibren van den Berg, Saco J de Visser, Lonneke Timmers, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 4, 2024
Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
Evert A Manders, Sibren van den Berg, Saco J de Visser, et al.
Frontiers in Pharmacology
|
November 8, 2021
Drug Repurposing for Rare Diseases: A Role for Academia
Sibren van den Berg, Saco de Visser, Hubert G M Leufkens, et al.
Cytotherapy
|
October 10, 2022
Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma
Frederick W Thielen, Renaud J S D Heine, Sibren van den Berg, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
March 17, 2023
[Medicine compounding in the pharmacy]
Yasmin Polak, Bart A W Jacobs, Sibren van den Berg, et al.
Orphanet Journal of Rare Diseases
|
October 28, 2025
Drivers of managed entry agreements to reduce reimbursement challenges of orphan medicinal products: the development of a matrix
Marcelien H E Callenbach, Sibren van den Berg, Alisa Hulsbosch, et al.
Orphanet Journal of Rare Diseases
|
September 5, 2020
Registries for orphan drugs: generating evidence or marketing tools?
Carla E M Hollak, Sandra Sirrs, Sibren van den Berg, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Nederlands Tijdschrift Voor Geneeskunde
|
September 15, 2021
[The assessment of the price of a medicine: not only on the basis of the value for the patient]
Carla E M Hollak, Sibren van den Berg, Lonneke Timmers, et al.
Drug Discovery Today
|
July 11, 2024
Reliable business case for repurposing of existing medicines requires key changes in government policies
Samuel J de Visser, Sibren van den Berg, Arend Mosterd, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 28, 2025
Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products
Sibren van den Berg, Carolina E Hollak, Lonneke Timmers, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 15, 2022
Author Reply
Sibren van den Berg, Saco J de Visser, Lonneke Timmers, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 4, 2024
Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
Evert A Manders, Sibren van den Berg, Saco J de Visser, et al.
Frontiers in Pharmacology
|
November 8, 2021
Drug Repurposing for Rare Diseases: A Role for Academia
Sibren van den Berg, Saco de Visser, Hubert G M Leufkens, et al.
Cytotherapy
|
October 10, 2022
Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma
Frederick W Thielen, Renaud J S D Heine, Sibren van den Berg, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
March 17, 2023
[Medicine compounding in the pharmacy]
Yasmin Polak, Bart A W Jacobs, Sibren van den Berg, et al.
Orphanet Journal of Rare Diseases
|
October 28, 2025
Drivers of managed entry agreements to reduce reimbursement challenges of orphan medicinal products: the development of a matrix
Marcelien H E Callenbach, Sibren van den Berg, Alisa Hulsbosch, et al.
Orphanet Journal of Rare Diseases
|
September 5, 2020
Registries for orphan drugs: generating evidence or marketing tools?
Carla E M Hollak, Sandra Sirrs, Sibren van den Berg, et al.
Page
of 2